Newly FDA-Approved Therapy Offers Kidney Cancer Patient a Path Forward

Chuck Stravin carries a white three-ring binder to all of his oncology appointments. Inside are his appointment notes, information about his treatment history, and the latest research and advancements regarding his disease. Nestled alongside these documents also sits a family photo of Stravin, his wife Liz, and their four daughters. Stravin’s family has been instrumental … Read more

Combination Immunotherapy Holds Promise for Patients with Rare Bladder Cancer

A woman recently came to Bradley McGregor, MD, an oncologist at Dana-Farber Cancer Institute, in severe pain with extreme fatigue. Her squamous cell bladder cancer, a rare type for which traditional treatment is generally less effective, had advanced, and it appeared that she had no other options. But timing is everything. McGregor was conducting a … Read more

The Latest Efforts in Precision Oncology for Advanced Prostate Cancer

The management of advanced prostate cancer is rapidly evolving with the application of precision treatments based on genomic testing of tumors’ altered DNA. With recent biomarker-driven drug approvals and increased clinical use of genomic testing, there are a number of opportunities to expand upon this framework. Researchers are calling for increased collaboration and new strategies. … Read more

Biomarker Search Reveals Unexpected Associations in Treatment of Advanced Kidney Cancer

Scientists are gratified when a clinical trial reveals whether one treatment — often an experimental therapy or drug combination — is superior to another. But researchers then often look more deeply into the data, searching for characteristics of tumors associated with a treatment’s effectiveness, or lack of it. In today’s world of precision medicine, identifying … Read more

Researchers Identify New Source of Drug Resistance in Prostate Cancer

For designers of targeted drugs, the biggest bullseye in prostate cancer has been the androgen receptor — a specialized net on prostate cells that snares androgen molecules to spur the cells’ growth. Drugs that block, or inhibit, the receptor can halt the cancer, but not all patients benefit from them, and nearly all those who … Read more

Nobel Prize Research Was a Winning Formula for Patient with Kidney Cancer

Early on an October morning, Shaun Tierney started a promising new treatment for his stage IV kidney cancer. Anxious to tell his longtime oncologist, he texted Toni Choueiri, MD, director of the Lank Center for Genitourinary Oncology at Dana-Farber. What he didn’t expect was that Choueiri would have his own big news: “Kaelin … Nobel … Read more

From the Military to Improving the Future of Cancer Care

There was a time when Bradley McGregor, MD, had what many would consider an unusual morning routine for an oncologist. Getting ready for work included putting on nearly 60 pounds of body armor, donning a tactical helmet, and grabbing his assault rifle before heading out the door. His commute took him from an American compound, … Read more

New Drug Target Found in Subset of Metastatic Prostate Cancers

Medically reviewed by Himisha Beltran, MD Prostate cancer, when diagnosed early, can be a very treatable disease. Even advanced prostate cancer has treatment options. But some advanced, metastatic prostate cancers become resistant to standard therapies by shapeshifting into a different type of cancer, called small cell neuroendocrine prostate cancer. These neuroendocrine tumors tend to be … Read more

New study uncovers strategy for defusing castration-resistant prostate cancer

Cancer is often fueled by hormones, including the male sex hormone testosterone, which spur tumor growth in most forms of prostate cancer. Doctors can defuse this destructive relationship, typically with drugs (or sometimes surgery), but frequently, the tumors adapt or evolve, devising ways to incite cancer growth even in the absence of hormone-driven signals. These … Read more